The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Progress and unmet needs in the treatment of t(4;14) multiple myeloma
Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses progress in the management of patients with multiple myeloma with translocation 4;14 (t(4;14)). Dr D’Agostino highlights that isolated t(4;14) now has a similar outcome to standard risk, but more progress is needed for patients with double-hit cytogenetics and those with late disruption of NSD2. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Therapies in myeloma are nowadays tailored on transplant eligibility still, so we have not a specific treatment available in the clinic that you can propose to these patients. However, with the novel quadruplets, also this subgroup of patients improved its prognosis, especially when t(4;14) is not coming with other high-risk cytogenetic alterations. So isolated t(4;14) nowadays has a very similar outcome compared to the standard risk...
Therapies in myeloma are nowadays tailored on transplant eligibility still, so we have not a specific treatment available in the clinic that you can propose to these patients. However, with the novel quadruplets, also this subgroup of patients improved its prognosis, especially when t(4;14) is not coming with other high-risk cytogenetic alterations. So isolated t(4;14) nowadays has a very similar outcome compared to the standard risk. We have still to make progress on the double-hit patients and those with the late disruption of NSD2.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
